Fabry disease and G6PD in three family members with priapism: is the nitric oxide pathway to blame?

Rebecca Backenroth1, Ezekiel H Landau, Miri Goren

  • 1Department of Nephrology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.

Insights

Priapism may be a clinical symptom of Fabry disease, a genetic disorder affecting multiple systems. The nitric oxide pathway may link Fabry disease and glucose-6-phosphate dehydrogenase deficiency to priapism.

Area of Science:

  • Genetics and rare diseases
  • Vascular biology
  • Metabolic disorders

Background:

  • Fabry disease is an X-linked disorder caused by alpha-galactosidase A deficiency, leading to glycosphingolipid accumulation.
  • This accumulation primarily affects vascular endothelium, impacting cardiovascular, renal, and neurologic systems.

Observation:

  • A familial cluster of priapism was observed in three males with Fabry disease and glucose-6-phosphate dehydrogenase (G6PD) deficiency.
  • Literature review identified six additional cases of priapism in males with Fabry disease and two with G6PD deficiency.

Findings:

  • Priapism is a rare but reported manifestation in males within the Fabry registry.
  • A potential link between Fabry disease, G6PD deficiency, and priapism is suggested through derangements in the nitric oxide (NO) pathway.

Implications:

  • Priapism should be considered a potential clinical symptom in patients with Fabry disease.
  • Fabry disease warrants inclusion in the differential diagnosis for priapism.
  • Further research is needed to elucidate the role of NO metabolism in Fabry disease manifestations, especially concerning G6PD deficiency.
Abstract

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Activation and Inactivation of G Proteins01:22

Activation and Inactivation of G Proteins

Heterotrimeric G proteins are guanine nucleotide-binding proteins. As the name suggests, heterotrimeric G proteins are composed of three subunits: alpha, beta, and gamma. They remain GDP-bound or GTP-bound inside the cells and switch between inactive/active states. The Gα subunit possesses the nucleotide-binding pocket that binds guanine nucleotides and switches between GDP or GTP-bound states. In contrast, the Gꞵ and Gγ subunits are always bound together with high affinity and are together...